Surrozen Inc. (SRZN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Surrozen Inc. (SRZN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.44

0.12 (1.06%)

At close: Jan 14, 2025, 3:59 PM

11.19

-2.19%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	10.51
Market Cap	37.18M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-16.94
PE Ratio (ttm)	-0.68
Forward PE	n/a
Analyst	Buy

Ask	17.9
Volume	53,125
Avg. Volume (20D)	44,878
Open	11.97
Previous Close	11.32
Day's Range	10.20 - 11.97
52-Week Range	6.00 - 18.17
Beta	undefined

About SRZN

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 11, 2021

Employees 42

Stock Exchange NASDAQ

Ticker Symbol SRZN

Website https://www.surrozen.com

Analyst Forecast

According to 1 analyst ratings, the average rating for SRZN stock is "Buy." The 12-month stock price forecast is $45, which is an increase of 293.36% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago · Source

+19.44%

Surrozen shares are trading higher after Guggenhei... Unlock content with Pro Subscription

3 months ago · Source

+8.7%

Surrozen shares are trading higher after the company announced it earned a $10 million payment as part of a collaboration with Boehringer that is advancing the development of SZN-413 for retinal vascular diseases.

News

9 months ago · 247wallst.com

Huge Insider Buying in Media by Warren Buffet and More

Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks, even with shares in retreat.

1 year ago · zacks.com

Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher

Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among...

1 year ago · zacks.com

5 Top Stocks Likely to Come Up With Earnings Beat

These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).

1 year ago · zacks.com

New Strong Buy Stocks for April 12th

CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.

1 year ago · pennystocks.com

How to Diversify Your Penny Stock Investments

Use these tips for diversifying your investments in penny stocks The post How to Diversify Your Penny Stock Investments appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

1 year ago · pennystocks.com

Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now

High volume penny stocks to watch right now. The post Penny Stocks To Buy?

2 years ago · zacks.com

Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know

Surrozen, Inc. (SRZN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 years ago · benzinga.com

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Surrozen Inc (NASDAQ: SRZN) announced that preclinical data from its inflammatory bowel disease (IBD) program, SZN-1326, were presented during the 2021 United European Gastroenterology Week. Related: ...

3 years ago · invezz.com

Here's why Surrozen shares are up more than 50% on Tuesday

Almost a month after Surrozen Inc (NASDAQ: SRZN) completed its business combination with a special purpose acquisition company (SPAC), Consonance-HFW Acquisition Corp, Stifel assumed coverage of the b...

3 years ago · benzinga.com

See Why Surrozen Stock Is Surging On Tuesday

Stifel initiated coverage of Surrozen Inc (NASDAQ: SRZN) with a Buy rating and $19 price target. The regenerative medicine biotech started trading recently on NASDAQ via SPAC deal with Consonance-HFW...